GlassScriptPhysician profile
Vinod Kripalu
NPI 1295740033
$1,527.85
in general payments reported to CMS, 2019-2025
27 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $210 · 2021: $135 · 2022: $36.19 · 2023: $124 · 2024: $275 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.18 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $190.07 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $148.96 | 2024 | Crosser Iq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $129.06 | 2019-2024 | Airsupra |
| Novo Nordisk INC | $89.45 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $88.00 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $82.26 | 2019-2023 | |
| Glaxosmithkline, LLC. | $80.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $67.30 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $67.20 | 2019-2021 | |
| Abbott Laboratories | $64.18 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.94 | 2019-2023 | Jardiance |
| Exact Sciences Corporation | $47.81 | 2024-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $42.27 | 2025 | Vivitrol |
| Astellas Pharma US INC | $34.42 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $32.85 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $22.79 | 2025 | Voquezna |
| Neos Therapeutics, LP | $20.60 | 2021 | |
| Allergan, INC. | $19.59 | 2020 | |
| Abbvie INC. | $18.17 | 2023 | |
| Sanofi-Aventis U.S. LLC | $17.12 | 2019 | |
| Linus Health, INC. | $16.82 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $16.52 | 2021 | |
| Seqirus USA INC | $16.20 | 2019 | |
| Amgen INC. | $15.00 | 2019 | |
| Bausch Health US, LLC | $13.39 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Kripalu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.